{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:58:39Z","timestamp":1787003919678,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2002,2,1]]},"DOI":"10.1038\/sj.bmt.1703363","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T14:14:42Z","timestamp":1031235282000},"page":"303-312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan\/GM-CSF or radiotherapy and consolidation chemotherapy"],"prefix":"10.1038","volume":"29","author":[{"given":"AP","family":"Rapoport","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Meisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Sarkodee-Adoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Fassas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SR","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Mookerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Takebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Heyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Badros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Hudes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Ruehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Kight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"MacFadden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Cottler-Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Tricot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,3,4]]},"reference":[{"key":"BF1703363_CR1","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.7326\/0003-4819-114-12-1059","volume":"114","author":"A Surbone","year":"1991","unstructured":"Surbone A, Armitage JO, Gale RP . Autotransplantation in lymphoma: better therapy for healthier patients? Ann Intern Med 1991 114: 1059 1060","journal-title":"Ann Intern Med"},{"key":"BF1703363_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1200\/JCO.1992.10.2.210","volume":"10","author":"DL Longo","year":"1992","unstructured":"Longo DL, Duffey PL, Young RC et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy. The low probability for cure J Clin Oncol 1992 10: 210 218","journal-title":"J Clin Oncol"},{"key":"BF1703363_CR3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1200\/JCO.1993.11.6.1085","volume":"11","author":"C Wheeler","year":"1993","unstructured":"Wheeler C, Strawderman M, Ayash L et al. Prognostic factors for treatment outcome in autotransplantation of intermediate grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide J Clin Oncol 1993 11: 1085 1091","journal-title":"J Clin Oncol"},{"key":"BF1703363_CR4","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1200\/JCO.1994.12.12.2559","volume":"12","author":"CJ Weaver","year":"1994","unstructured":"Weaver CJ, Peterson FB, Appelbaum FR et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma J Clin Oncol 1994 12: 2559 2566","journal-title":"J Clin Oncol"},{"key":"BF1703363_CR5","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1200\/JCO.1994.12.12.2552","volume":"12","author":"SJ Horning","year":"1994","unstructured":"Horning SJ, Negrin RS, Chao NJ et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma J Clin Oncol 1994 12: 2552 2558","journal-title":"J Clin Oncol"},{"key":"BF1703363_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1200\/JCO.2001.19.2.406","volume":"19","author":"JM Vose","year":"2001","unstructured":"Vose JM, Zhang MJ, Rowlings P et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry J Clin Oncol 2001 19: 406 413","journal-title":"J Clin Oncol"},{"key":"BF1703363_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/sj.bmt.1701624","volume":"6","author":"CH Moskowitz","year":"1999","unstructured":"Moskowitz CH, Nimer SD, Glassman JR et al. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma Bone Marrow Transplant 1999 6: 561 567","journal-title":"Bone Marrow Transplant"},{"key":"BF1703363_CR8","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood.V96.7.2399","volume":"96","author":"T Kewalramani","year":"2000","unstructured":"Kewalramani T, Zelenetz AD, Hedrick EE et al. High-dose chemotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis Blood 2000 96: 2399 2404","journal-title":"Blood"},{"key":"BF1703363_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1200\/JCO.1998.16.1.48","volume":"16","author":"PJ Stiff","year":"1998","unstructured":"Stiff PJ, Dahlberg S, Forman SJ et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens \u2013 a Southwest Oncology Group trial J Clin Oncol 1998 16: 48 55","journal-title":"J Clin Oncol"},{"key":"BF1703363_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/sj.bmt.1702433","volume":"25","author":"EA Copelan","year":"2000","unstructured":"Copelan EA, Penza SL, Pohlman B et al. Autotransplantation followoing busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma Bone Marrow Transplant 2000 25: 1243 1248","journal-title":"Bone Marrow Transplant"},{"key":"BF1703363_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1046\/j.1365-2141.2001.02705.x","volume":"113","author":"CI Chen","year":"2001","unstructured":"Chen CI, Crump M, Tsang R et al. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma Br J Haematol 2001 113: 202 208","journal-title":"Br J Haematol"},{"key":"BF1703363_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/sj.bmt.1700772","volume":"19","author":"AP Rapoport","year":"1997","unstructured":"Rapoport AP, Lifton R, Constine LS et al. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors Bone Marrow Transplant 1997 19: 883 890","journal-title":"Bone Marrow Transplant"},{"key":"BF1703363_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/sj.bmt.1701325","volume":"22","author":"JE Lancet","year":"1998","unstructured":"Lancet JE, Rapoport AP, Brasacchio R et al. Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors Bone Marrow Transplant 1998 22: 265 271","journal-title":"Bone Marrow Transplant"},{"key":"BF1703363_CR14","first-page":"3101","volume":"17","author":"JW Sweetenham","year":"1999","unstructured":"Sweetenham JW, Carella AM, Taghipour G et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation Lymphoma Working Party J Clin Oncol 1999 17: 3101 3109","journal-title":"Lymphoma Working Party J Clin Oncol"},{"key":"BF1703363_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/10428199909145708","volume":"35","author":"Fleming Dr","year":"1999","unstructured":"Fleming Dr, Wolff SN, Fay JW et al. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group Leuk Lymphoma 1999 35: 91 98","journal-title":"Leuk Lymphoma"},{"key":"BF1703363_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1200\/JCO.1999.17.2.534","volume":"17","author":"HM Lazarus","year":"1999","unstructured":"Lazarus HM, Rowlings PA, Zhang M-J et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the autologous blood and marrow transplant registry J Clin Oncol 1999 17: 534 545","journal-title":"J Clin Oncol"},{"key":"BF1703363_CR17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s002770000190","volume":"79","author":"K Neben","year":"2000","unstructured":"Neben K, Hohaus S, Goldschmidt H et al. High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors Ann Hematol 2000 79: 547 555","journal-title":"Ann Hematol"},{"key":"BF1703363_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bmt.1702796","volume":"27","author":"HM Lazarus","year":"2001","unstructured":"Lazarus HM, Loberiza FR Jr, Zhang MJ et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR) Bone Marrow Transplant 2001 27: 387 396","journal-title":"Bone Marrow Transplant"},{"key":"BF1703363_CR19","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.2001.19.5.1395","volume":"19","author":"A Sureda","year":"2001","unstructured":"Sureda A, Arranz R, Iriondo A et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas\/Transplante Autologo de Medula Osea Spanish Cooperative Group J Clin Oncol 2001 19: 1395 1404","journal-title":"J Clin Oncol"},{"key":"BF1703363_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/jnci\/81.2.116","volume":"81","author":"LJ Goldstein","year":"1989","unstructured":"Goldstein LJ, Galski H, Fojo A et al. Expression of a multidrug resistant gene in human cancers J Natl Cancer Inst 1989 81: 116 124","journal-title":"J Natl Cancer Inst"},{"key":"BF1703363_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1200\/JCO.1991.9.1.17","volume":"9","author":"TP Miller","year":"1991","unstructured":"Miller TP, Grogan TM, Dalton WS et al. P-glycoprotein in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil J Clin Oncol 1991 9: 17 24","journal-title":"J Clin Oncol"},{"key":"BF1703363_CR22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.V89.2.601","volume":"89","author":"WH Wilson","year":"1997","unstructured":"Wilson WH, Teruya-Feldstein J, Fest T et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas Blood 1997 89: 601 609","journal-title":"Blood"},{"key":"BF1703363_CR23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood.V87.1.265.265","volume":"87","author":"O Hermine","year":"1996","unstructured":"Hermine O, Haioun C, Lepage E for the Groupe d'Etude des Lymphomes de l'Adulte (GELA) et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma Blood 1996 87: 265 272","journal-title":"Blood"},{"key":"BF1703363_CR24","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1200\/JCO.1996.14.7.2131","volume":"14","author":"MHH Kramer","year":"1996","unstructured":"Kramer MHH, Hermans J, Parker J et al. Clinical significance of bcl-2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study JCO 1996 14: 2131 2138","journal-title":"JCO"},{"key":"BF1703363_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1126\/science.275.5298.343","volume":"275","author":"JN Weinstein","year":"1997","unstructured":"Weinstein JN, Myers TG, O'Connor PM et al. An information-intensive approach to the molecular pharmacology of cancer Science 1997 275: 343 349","journal-title":"Science"},{"key":"BF1703363_CR26","first-page":"4024","volume":"48","author":"V Heinemann","year":"1988","unstructured":"Heinemann V, Hertel LW, Grindey GB et al. Comparisons of the cellular pharmacokinetics and toxicity of 2\u20192\u2019-difluorodeoxycytidine and 1-\u03b2-D-arabinofuranosylcytosine Cancer Res 1988 48: 4024 4031","journal-title":"Cancer Res"},{"key":"BF1703363_CR27","first-page":"4417","volume":"50","author":"LW Hertel","year":"1990","unstructured":"Hertel LW, Boder GB, Kroin S et al. Evaluation of the antitumor activity of gemcitabine (2\u20322\u2032-difluoro-2\u2032deoxycytidine) Cancer Res 1990 50: 4417 4422","journal-title":"Cancer Res"},{"key":"BF1703363_CR28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s002800050467","volume":"38","author":"WR Waud","year":"1996","unstructured":"Waud WR, Gilbert KS, Grindey GB et al. Lack of in vivo crossresistance with gemcitabine against drug-resistant murine P388 leukemias Cancer Chemother Pharmacol 1996 38: 178 180","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1703363_CR29","first-page":"21a","volume":"16","author":"A Santoro","year":"1997","unstructured":"Santoro A, Devizzi L, Bonfante V et al. Phase II study with gemcitabine in pretreated patients with Hodgkin's (HD) and non-Hodgkin's lymphomas (NHL): results of a multicenter study Proc Am Soc Clin Oncol 1997 16: 21a (Abstr. 71)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF1703363_CR30","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V81.12.3474.3474","volume":"15","author":"BS Charak","year":"1993","unstructured":"Charak BS, Agah R, Mazumder A . Granulocyte\u2013macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation Blood 1993 15: 3474 3479","journal-title":"Blood"},{"key":"BF1703363_CR31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/BF01525989","volume":"39","author":"P Ragnhammar","year":"1994","unstructured":"Ragnhammar P, Frodin JE, Trotta PP, Mellstedt H . Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte\/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies Cancer Immunol Immunother 1994 39: 254 262","journal-title":"Cancer Immunol Immunother"},{"key":"BF1703363_CR32","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/0145-2126(96)00025-2","volume":"20","author":"A Nagler","year":"1996","unstructured":"Nagler A, Shur I, Barak V, Fabian I . Granulocyte\u2013macrophage colony-stimulating factor dependent monocyte-mediated cytotoxicity post-autologous bone marrow transplantation Leuk Res 1996 20: 637 643","journal-title":"Leuk Res"},{"key":"BF1703363_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0022-1759(00)00346-X","volume":"248","author":"B Stockmeyer","year":"2001","unstructured":"Stockmeyer B, Elsasser D, Dechant M et al. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies J Immunol Methods 2001 248: 103 111","journal-title":"J Immunol Methods"},{"key":"BF1703363_CR34","first-page":"586a","volume":"88","author":"NC Munshi","year":"1996","unstructured":"Munshi NC, Desikan KR, Jagannath S et al. Dexamethasone, cyclophosphamide, etoposide and Cis-platinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation (AT) Blood 1996 88: (Suppl. 1) 586a (Abstr. 2331)","journal-title":"Blood"},{"key":"BF1703363_CR35","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1200\/JCO.2000.18.13.2615","volume":"18","author":"A Santoro","year":"2000","unstructured":"Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study J Clin Oncol 2000 18: 2615 2619","journal-title":"J Clin Oncol"},{"key":"BF1703363_CR36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1139\/o94-061","volume":"72","author":"S Haldar","year":"1994","unstructured":"Haldar S, Jena N, Croce CM . Antiapoptosis potential of bcl-2 oncogene by dephosphorylation Biochem Cell Biol 1994 72: 455 462","journal-title":"Biochem Cell Biol"},{"key":"BF1703363_CR37","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1200\/JCO.1995.13.2.381","volume":"13","author":"WH Wilson","year":"1995","unstructured":"Wilson WH, Chabner BA, Bryan TG et al. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas J Clin Oncol 1995 13: 381 386","journal-title":"J Clin Oncol"},{"key":"BF1703363_CR38","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1046\/j.1365-2141.1997.d01-2012.x","volume":"96","author":"A Younes","year":"1997","unstructured":"Younes A, Ayoub JP, Sarris A et al. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial Br J Haematol 1997 96: 328 332","journal-title":"Br J Haematol"},{"key":"BF1703363_CR39","first-page":"21a","volume":"16","author":"A Younes","year":"1997","unstructured":"Younes A, Preti A, Romaguera J et al. Activity of taxol and high-dose cytoxan with granulocyte colony-stimulating factor (G-CSF) in 54 patients with relapsed\/refractory non-Hodgkin's lymphoma (NHL) Proc Am Soc Clin Oncol 1997 16: (Suppl. 1) 21a (Abstr. 74)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF1703363_CR40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Nonparametric estimation from incomplete observation J Am Stat Assoc 1958 53: 457 481","journal-title":"J Am Stat Assoc"},{"key":"BF1703363_CR41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"74","author":"DR Cox","year":"1972","unstructured":"Cox DR . Regression models and life tables J R Stat Soc B 1972 74: 187 220","journal-title":"J R Stat Soc B"},{"key":"BF1703363_CR42","doi-asserted-by":"crossref","first-page":"384a","DOI":"10.1182\/blood.V96.2.384","volume":"96","author":"SM Horwitz","year":"2000","unstructured":"Horwitz SM, Breslin S, Negrin RS et al. Adjuvant rituximab after autologous peripheral blood stem cell transplant (APBSCT) results in delayed immune reconstitution without increase in infectious complications Blood 2000 96: (Suppl. 1) 384a (Abstr. 1657)","journal-title":"Blood"},{"key":"BF1703363_CR43","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2000.18.23.3918","volume":"18","author":"AM Carella","year":"2000","unstructured":"Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma J Clin Oncol 2000 18: 3918 3924","journal-title":"J Clin Oncol"},{"key":"BF1703363_CR44","first-page":"407","volume":"11","author":"GG Laport","year":"2000","unstructured":"Laport GG, Liebowitz DN, Williams SF et al. Adoptive transfer of CD3\/CD28 ex vivo costimulated T-cells in patients with relapsed\/refractory non-Hodgkin's lymphoma (NHL) following high dose chemotherapy (HDC) with CD34-selected peripheral blood stem cell (PBSC) support Blood 2000 11: (Suppl. 1) 407 (Abstr. 1751)","journal-title":"Blood"},{"key":"BF1703363_CR45","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1046\/j.1365-2141.2000.01958.x","volume":"108","author":"S Titzer","year":"2000","unstructured":"Titzer S, Christensen O, Manzke O et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects Br J Haematol 2000 108: 805 816","journal-title":"Br J Haematol"},{"key":"BF1703363_CR46","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood.V93.7.2411","volume":"93","author":"VL Reichardt","year":"1999","unstructured":"Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma \u2013 a feasibility study Blood 1999 93: 2411 2419","journal-title":"Blood"},{"key":"BF1703363_CR47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<215::AID-IJC12>3.0.CO;2-Q","volume":"83","author":"SH Lim","year":"1999","unstructured":"Lim SH, Bailey-Wood R . Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma Int J Cancer 1999 83: 215 222","journal-title":"Int J Cancer"},{"key":"BF1703363_CR48","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V89.9.3129","volume":"89","author":"FJ Hsu","year":"1997","unstructured":"Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial Blood 1997 89: 3129 3135","journal-title":"Blood"},{"key":"BF1703363_CR49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nm0196-52","volume":"2","author":"FJ Hsu","year":"1996","unstructured":"Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells Nat Med 1996 2: 52 58","journal-title":"Nat Med"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703363","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T05:34:52Z","timestamp":1733549692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2,1]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,2,1]]}},"alternative-id":["BF1703363"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703363","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2,1]]},"assertion":[{"value":"12 August 2001","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2001","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}